Projected Return on Investment From Implementation of a Lifestyle Intervention to Reduce Adverse Pregnancy Outcomes.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
entrez:
6
9
2022
pubmed:
7
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
Structured antenatal diet and physical activity interventions have been shown to be associated with reduced adverse pregnancy outcomes and recommended to be routinely offered to all pregnant women. The health cost implications of population-level implementation are unclear. To estimate the budget impact associated with integrating structured diet and physical activity interventions into routine antenatal care. This economic evaluation was conducted from the perspective of Australian health funders. An open-source decision-tree model was constructed to compare the projected budget outcomes of implementing lifestyle intervention vs usual care. Scenario, deterministic, and probabilistic sensitivity analysis were completed. The study setting was Australian health services, and the study population was all Australian women projected to give birth in the years 2022 to 2026 (approximately 330 000 per year). Structured diet and physical activity intervention provided by trained health professionals, integrated into routine antenatal care. Comparator was usual care, which currently in Australia does not include routine structured lifestyle interventions. Return on investment (ROI) ratio for lifestyle intervention (cost of intervention divided by cost savings attributable to reduced maternal and infant adverse events) from the perspective of Australian health care funders. Adverse events were obtained from a published meta-analysis and population data. Costs were estimated from aggregate trial data and clinical pathways and valued at the year incurred. Intervention offered an ROI ratio of 4.75 over the 5-year program; hence every Australian dollar spent on implementation produced an estimated return of A$4.75. The projected total 5-year intervention cost was A$205 million ($151 million), with cost offsets (from reduced incidence of adverse pregnancy outcomes) of A$1022 million ($755 million), and health budget savings of A$807 million (95% CI, A$129 million to A$1639 million) ($596 million [95% CI, $95 million to $1211 million]); 93.3% of the 10 000 iterations were within cost saving, and results were robust to scenario and sensitivity analyses. This economic evaluation found that providing access to structured diet and physical activity lifestyle interventions for all pregnant Australian women was estimated to provide strong return on investment for health funders. The open-source model developed can be used by other jurisdictions and health services to explore cost implications of implementation within their patient population.
Identifiants
pubmed: 36066890
pii: 2795964
doi: 10.1001/jamanetworkopen.2022.30683
pmc: PMC9449797
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2230683Références
Obstet Gynecol Int. 2014;2014:297397
pubmed: 25136369
JAMA. 2021 May 25;325(20):2087-2093
pubmed: 34032823
Value Health. 2017 Jan;20(1):100-106
pubmed: 28212950
Implement Sci. 2021 Aug 3;16(1):75
pubmed: 34344411
JAMA Intern Med. 2022 Feb 01;182(2):106-114
pubmed: 34928300
Pharmacoecon Open. 2020 Sep;4(3):499-510
pubmed: 32026397
Am J Obstet Gynecol. 2017 Mar;216(3):250.e1-250.e14
pubmed: 28041927
Lancet. 2018 Oct 13;392(10155):1349-1357
pubmed: 30322585
JAMA. 2017 Jun 06;317(21):2207-2225
pubmed: 28586887
Value Health. 2014 Jan-Feb;17(1):5-14
pubmed: 24438712
Value Health. 2022 Feb;25(2):194-202
pubmed: 35094792
Obstet Gynecol. 2019 Mar;133(3):541-551
pubmed: 30801455
Obes Rev. 2022 Apr;23(4):e13406
pubmed: 34927351
Lancet. 2018 Oct 13;392(10155):1341-1348
pubmed: 30322584
Sci Rep. 2016 Mar 10;6:22895
pubmed: 26961675
JAMA. 2021 May 25;325(20):2094-2109
pubmed: 34032824
BMC Med. 2018 Aug 31;16(1):153
pubmed: 30165842
J Clin Med. 2020 Dec 17;9(12):
pubmed: 33348671
Nutr Metab Cardiovasc Dis. 2021 May 6;31(5):1427-1433
pubmed: 33846005
Pregnancy Hypertens. 2020 Jul;21:197-199
pubmed: 32634609